- Molecular NameFurazolidone
- SynonymNitrofurazolidone; Nitrofurazolidonum; USAF EA-1
- Weight225.16
- Drugbank_IDDB00614
- ACS_NO67-45-8
- Show 3D model
- LogP (experiment)-0.05
- LogP (predicted, AB/LogP v2.0)1.17
- pkaN/A
- LogD (pH=7, predicted)1.17
- Solubility (experiment)0.04 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.27
- LogSw (predicted, AB/LogsW2.0)0.1
- Sw (mg/ml) (predicted, ACD/Labs)0.12
- No.of HBond Donors0
- No.of HBond Acceptors8
- No.of Rotatable Bonds3
- TPSA103.87
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antibacterial.
- Absorption_valueN/A
- Absorption (description)Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmFurazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.
- Half life10 min
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityReactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
- LD50 (rat)N/A
- LD50 (mouse)LD50=1807 (peroral)